HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Haitian Pharmaceutical (688302.SH) announced that on December 7, 2025, the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List (2025)" (hereinafter referred to as the "National Medical Insurance Drug List"). The company's independently developed daunorubicin capsules have been included in the National Medical Insurance Drug List for the first time through national medical insurance negotiations, and the list will be implemented from January 1, 2026. Daunorubicin soft capsules (formerly known as HC-1119 soft capsules) are a class 1 new drug developed independently by the company for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a second-generation androgen receptor (AR) inhibitor and has received major funding support from the National Major New Drug Creation Science and Technology Major Project.